Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Fundamentals of Liver Disease - Non-Alcoholic Fatty Liver Disease (NAFLD) & Non-Alcoholic Steatohepatitis 2.0

    Contains 31 Component(s), Includes Credits

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    There is currently an anticipated shortage of trained providers capable of diagnosing and treating different liver diseases. As a result of this increased demand and limited specialists in the field, more and more front line providers are faced with these patients and do not have the experience or resources that will allow them to manage them appropriately.

    The overall goal is to improve patient care by increasing learner competence and confidence in both proper patient identification and assessment and increasing learner performance in therapeutic options and on-treatment management strategies for patients. Patient outcomes will be improved as a result of the improvements in more providers understanding these key components in the management and care of patients with liver diseases.

    Key topic areas:
    NAFLD: Diagnosis and Identification of Those at Risk of Disease Progression
    Pathogenesis of Non-alcoholic Steatohepatitis
    Non-Invasive Determination of Advanced Disease in NAFLD
    Lifestyle Interventions: Setting Goals and Recommendations
    Comorbidities in NAFLD: Cardiovascular Disease, Sleep Apnea, and Chronic Kidney Disease
    Bariatric Surgery: Is the Cure for NASH in the OR?
    Managing NASH Cirrhosis and Assessment for Liver Transplant
    Current Pharmacological Treatment Options for Non-Alcoholic Steatohepatitis (NASH)
    Emerging Treatments for Non-Alcoholic Steatohepatitis

    Release date: June 15, 2020
    Expiration date: June 14, 2023
    Time to complete each module: 30 minutes

    CREDITS OFFERED

    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Continuing Education (CE): For a maximum of 4.50 Contact Hour
    You may only earn one Continuing Education Credit type- either CE or CME

    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points

    COMPONENTS
    Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations:
    -9 online, narrated modules 15 to 20 minutes in length 
    -Pre- and post-test questions for each module
    -Evaluation for CE or CME credit offering 

    DIRECTIONS
    Click "Activate" to register for the enduring material. Review all section tabs before you begin. Select module of interest. Complete necessary components to claim either CE or CME, and MOC.

    COPYRIGHT
    All faculty in this activity have given their permission for publication ©2020 AASLD. 

    CONTACT INFORMATION
    For questions on CME and  MOC content or LiverLearning®, contact online_education@aasld.org
    For questions on CE credit for this enduring material, contact Certificate@AmedcoEmail.com

    Learning Objective:
    • Identify patients with liver disease, specifically NASH/NAFLD
    • Apply diagnostic tests appropriately
    • Discuss important counseling
    • Recognize treatment/referral priorities
    • Identify first line therapies for NASH/NAFLD
    • Refer to specialist in a timely and appropriate fashion

    This curriculum was developed for Primary Care Providers and any other healthcare provider interested in liver disease.

    Hepatologists
    Gastroenterologists
    Nurses
    Nurse Practitioners
    Pharmacists
    Physician Assistants
    Transplant Coordinators
    Surgeons
    Fellows/Trainees
    Primary Care Physicians
    Other healthcare providers

    CREDITS OFFERED 
    Continuing Medical Education (CME): For a maximum of 4.50 AMA PRA Category 1 Credits™ 
    Maintenance of Certification (MOC): For a maximum of 4.50 MOC Points
    Continuing Education (CE): For a maximum of 4.50 Contact Hours

    ACCREDITATION AND DESIGNATION STATEMENTS Continuing Medical Education (CME) 
    The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this enduring activity for a maximum of 4.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Maintenance of Certification (MOC) Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    image

    Continuing Education (Nursing Contact Hours)  In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the American Association for the Study of Liver Diseases.  Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring material activity for a maximum of 4.50 contact hours for nurses. Learners should claim only the credit commensurate with the extent of their participation in the activity.

    CLAIMING CME CREDITS Physicians and other health care professionals for a maximum of 4.50 AMA PRA Category 1 Credits™ for this enduring continuing medical education material must completed by June 14, 2023

    CLAIMING ABIM MOC POINTS  Physicians seeking ABIM MOC credit must complete the enduring material by June 14, 2023. Requests for MOC after this date will not be honored. MOC Points will be reported to the ABIM by the end of each month through July 2023 for individuals who successfully complete MOC.

    CLAIMING CE CREDITS Nurses for a maximum of 4.50 contact hours for this enduring continuing education material must be completed by June 14, 2023

    HOW TO EARN AND CLAIM MOC POINTS For each module that you wish to claim MOC points for you must:

                 o    Complete the pre-test

                 o    Watch video presentation

                 o    Complete the post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score.)

                 o    Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity.)

    MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile.

    MOC points are available for ABIM board certified physicians only.

    DISCLOSURE OF CONFLICTS OF INTEREST
    AASLD requires all individuals who are in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosures are collected prior to the start of the educational activity. Any potential conflicts of interest that exist are resolved prior to implementation of the activity. All disclosures are made available and communicated to the leaner prior the activity beginning.

    The enduring material organizers, faculty, reviewers and staff have reported the following disclosures:

    Mary E. Rinella, MD, FAASLD
    Faculty
    Consulting: AbbVie, NuSirt, NGM Biopharmaceuticals, Novartis, Gilead, Intercept, Genfit, Enanta, BMS, Immuron, CymaBay, Merck, Viking, Madrigal, Genesis, Metacrine, Allergan, Thetis, Fractyl, 3vBio, Coherus, Terns, Boehringer Ingelheim and Takeda
    Editorial Board: Hepatology, Clinical Liver Disease (guest associate editor), Seminars in Liver Disease (associate editor in 2017)

    Arun J. Sanyal, MD, MBBS
    Faculty
    Consulting: Novartis, Merck, BMS, Boehringer Ingelheim, Nitto Denko, Tobira, Intercept, Genfit, Aredelyx, Akarna, Syntlogic, Fractyl, Pfizer, Jannsen, Exalenz, Novo Nordisk, Nordic Bioscience, Lilly
    Grant/research support: Intercept, Gilead, Tobira, Novartis, Astra Zeneca, Merck, BMS
    Stock Options: Genfit
    President of Sanyal Bio

    Leon A. Adams, MBBS, FRACP, PhD
    Faculty
    Patents regarding Hepascore
    Employer has a licensing agreement with Quest Diagnostics regarding its commercialization

    Brent Neuschwander-Tetri, MD
    Faculty
    Consulting: Allergan, Allysta, Arrowhead, ARTham, Axcella, Blade, Boehringer-Ingelheim, Bristol-Myers Squibb, Conatus, Consynance, Cymabay, Durect, Enanta, Ferring, Fortress, Gelesis, Genfit, Gilead, High Tide, Histolndex, Intercept, Lipocine, Llama, Madrigal, Medimmune, Merck, Metacrine, Mundipharma, NGM, pH-Pharma, Prometheus and Siemens
    Grants/research support: Allergan, BMS, Cirius, Cymabay, Enanta, Galectin, Genfit, Gilead, Intercept, Madrigal, NGM and Prometheus

    Kathleen E. Corey, MD, MPH, MMSc
    Faculty
    Nothing to disclose

    Philippe Mathurin
    Faculty
    Financial Interests: MSD, Abbvie, Gilead Sciences, Bristol-Myers Squibb, Verlyx, Intercept, Janssen-Cilag and Bayer Healthcare pharmaceutical companies

    Kymberly D. Watt, MD

    Faculty
    Co-investigator for industry studies supported by Conatus, Intercept Pharmaceuticals and Gilead

    Dawn M. Torres, MD
    Faculty
    Nothing to disclose

    Raj Vuppalanchi, MD, FAASLD
    Faculty
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Sanjeeva Arora, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose 

    Lauren A. Beste, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Amanda J. Chaney, DNP, APRN, FNP-BC
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Royalities: Springer Publishing-Author

    Guadalupe Garcia-Tsao, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Advisory Board: Intercept, Conatus
    Scientific Consultant/Advisor to Industry or Commercial Enterprises, including Development of Education Presentations: Conatus, Galectin
    Research Grants: Intercept

    Leslie Hayes
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Minhhuyen Nguyen, MD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Vicki Shah, PA
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Scientific Consultant/Advisory to Industry or Commercial Enterprise, including Development of educational Presentations: Gilead, Intercept, AbbVie Advisory Board, Gilead Advisory Board

    Raj Vuppalanchi, MD, FAASLD
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Data Safety Monitoring Board for Industry or Commercial Enterprise: Enanta, Enyio and LabCorp/Covance
    Served as PI for multicenter clinical trials: Intercept, Gilead, Zydus Discovery, Novo Nordisk and Eli Lilly

    Susan Zapatka, MSN
    Fundamentals of Liver Disease Committee/Organizer/Reviewer
    Nothing to disclose

    Dominique Clayton
    AASLD Staff
    Nothing to disclose

    Denise Seise
    AASLD Staff
    Nothing to disclose

    Sheryl Morgan
    Amedco LLC Staff
    Nothing to disclose

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    DISCLAIMER
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement of Commercial Support:
    No commercial support was received for this enduring material activity.

  • 2020 Webinar: Hepatitis C: Infection Beyond the Liver

    Contains 2 Component(s) Recorded On: 05/19/2020

    Webinar hosted by the Hepatitis C Special Interest Group on May 19, 2020.

    Extrahepatic manifestations of HCV contribute to its increased overall mortality rate in those infected relative to those who aren’t; associated cardiovascular, neoplastic and renal manifestations can contribute significantly to a patient’s truncated lifespan beyond liver-related morbidity. This webinar will address the recognition and the treatment of extrahepatic manifestations of chronic HCV infection. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Miklos Z. Molnar

    Dr. Miklos Z. Molnar is an Hungarian-American Transplant Nephrologist and an Associate Professor of Medicine at University of Tennessee Health Science Center, Memphis, TN. He is also affiliated with James D. Eason Transplant Institute in Methodist University Hospital, also in Memphis. Dr. Molnar serves as Director of AST Transplant Nephrology Program at James D. Eason Transplant Institute in Methodist University Hospital.

    Dr. Molnar obtained his MD and PhD from Semmelweis University, Budapest, Hungary. He received additional medical training in Hungary and board certified in internal medicine, nephrology and transplant medicine in Europe. Dr Molnar immigrated to US in 2010, spent two years as post-doc fellow at Harbor UCLA, and obtained his US residency and transplant nephrology fellowship at University of Tennessee Health Science Center, Memphis, Tennessee and nephrology fellowship at University of Toronto, Toronto, Canada. Dr. Molnar is board certified in internal medicine and nephrology.

    Dr. Molnar is an author of more than 240 articles in a field of nephrology and transplant medicine. He serves as editorial board member in several journals, and current Associate Editor in Transplant International. He also served as PI in a recent R21 grant.

    Francesco Negro

    Francesco Negro is Professor at the Departments of Medicine and of Pathology and Immunology of the University Hospitals of Geneva, Switzerland. He obtained his Medical Degree in 1982 at the University of Torino, Italy, where he also completed his postgraduate education in Gastroenterology. He was Visiting Scientist and then Assistant Professor at the Georgetown University School of Medicine, Rockville, MD, USA from 1986 to 1989, and Guest Researcher at the Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA in 1989.

    After having spent some time back in Torino, he joined the University Hospitals of Geneva, Switzerland, in 1994. He was appointed Full Professor of the Faculty of Medicine, University of Geneva in 2014. His research interests focus on viral hepatitis, especially on the pathogenesis of metabolic alterations induced by the hepatitis C virus, i.e. steatosis and insulin resistance. More recently, he has participated into numerous collaborative works on epidemiology and public health issues related to viral hepatitis.

    He has participated in several clinical trials in acute and chronic HCV, authoring or co-authoring more than 300 peer-reviewed manuscripts in the field of hepatology. After serving as Educational Councilor within the Governing Board of the European Association for the Study of the Liver (EASL), he is currently Treasurer of EASL for the period 2019-2024. He is also chairing the Swiss Hepatitis C Cohort Study, and is member of the updating panels of the clinical practice guidelines for HCV of the EASL and of the World Health Organisation.

    Harrys A. Torres

    Harrys A. Torres, MD, FACP, FIDSA, is an Associate Professor of Medicine in the Department of Infectious Diseases, Infection Control and Employee Health and an Adjunct Associate Professor, Department of Gastroenterology, Hepatology, and Nutrition at the University of Texas MD Anderson Cancer Center in Houston, Texas. He is board-certified in internal medicine, and infectious disease, with additional accreditations on HIV/AIDS and Tropical Medicine and Hygiene. He is the founder and director of the Hepatitis C virus (HCV) clinic at MD Anderson, the first established clinic in the US, and likely in the world, devoted to managing HCV in cancer patients.

    Dr. Torres is a member of numerous national committees for professional societies such as the Infectious Diseases Society of America, American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver and the American Society for Blood and Marrow Transplantation. He is the secretary of the AASLD Special Interest Group on HCV and the principal investigator for multiple research grants. His research interest is to facilitate translational research in the prevention, detection, and treatment of HCV in patients with cancer and hematopoietic cell transplantation. His work addressed the fact that HCV is a neglected condition in cancer patients. Additionally, he has discovered new associations between HCV and other cancers (e.g. Head and Neck cancers). He has also documented the effectiveness, benefits, and safety of antiviral therapy in HCV-patients with cancer including those with hepatocellular carcinoma and B-cell non-Hodgkin lymphoma.

    Dr. Torres is co-author of more than 100 articles published in peer-reviewed journals, including CA: A Cancer Journal for Clinicians, Gastroenterology, HEPATOLOGY, Journal of Hepatology, Journal of the National Cancer Institute, Lancet Haematology, American Journal of Gastroenterology, Leukemia, Clinical Infectious Diseases, Blood, Nature Reviews Clinical Oncology, Cancer, Liver International, and Journal of Viral Hepatitis with many of his publications accompanied by editorials. He has presented almost 130 abstracts in international meetings and written 8 book chapters. His work on HCV has been awarded multiple times by the AASLD and American Society of Clinical Oncology among others. Dr. Torres lectures widely nationally and internationally on HCV in cancer patients and trains infectious diseases and gastroenterology fellows in the diagnosis and management of HCV in this special patient population. By providing evidence and innovative approaches, his body of work has changed the standard of care for HCV-infected cancer patients.

    Brian Pearlman (Moderator)

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

  • 2020 Webinar: Chronic Hepatitis C 101: The Basics

    Contains 2 Component(s) Recorded On: 04/28/2020

    Webinar hosted by the Hepatitis C Special Interest Group on April 28, 2020.

    As chronic hepatitis C infection therapy moves outside the realm of specialty care, more providers want to be well-versed in both identifying patients and treating them appropriately. This webinar is designed for the HCV-treating novice. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Lisa Catalli

    Lisa Catalli is a Nurse Practitioner at the University of California, San Francisco’s Viral Hepatitis Center and Liver Transplant Clinic. She earned her Master’s Degree from UCSF School of Nursing in 1995 and has been working in the field of Hepatology since 2010. She has been treating HCV since the dawn of direct-acting antiviral therapy, and served as a co-investigator in several multi-center clinical trials. Her expertise in HCV treatment has led to multiple educational and leadership activities in HCV elimination. She has worked to disseminate knowledge about HCV through mentoring students and didactic presentations and workshops. She is a key clinical faculty in the UCSF Project ECHO program which uses multi-point video conferencing to build knowledge-sharing networks with community providers to build the capacity for care of HCV patients throughout California.

    She is also part of an interdisciplinary team to improve access and linkage to HCV care through a creative, innovative model of mobile liver care clinic (UCSF DeLiver Care) that is co-localized at syringe exchange/medically assisted treatment centers for vulnerable populations. She has been a Hepatology Associates member of AASLD for 10 years with leadership roles in the HCV SIG and the Hepatology Associates Committee, serving on committees for the planning of AASLD educational programs, moderating educational sessions, and selecting NP/PA fellowship awards.

    Natarajan Ravendhran

    Dr. Ravendhran is a hepatologist in Baltimore, Maryland. He is trained in hepatology by Dr. Schiff at University of Miami. He is board-certified in gastroenterology and transplant hepatology. He is a medical director for the research department in Digestive Disease Associates in Baltimore. He holds faculty position at Johns Hopkins University as a clinical assistant professor in the department of medicine. He is a Fellow of American Association for Study of Liver Diseases.

    He is actively involved in clinical trials, teaching and having a busy clinical practice. He has conducted more than 100 clinical trials in hepatology regarding chronic hepatitis C treatment, hepatitis B treatment and currently involved in many clinical trials with non-alcoholic fatty liver disease. He has published in Journal of Hepatology, Journal of American College of Gastroenterology, and New England Journal of Medicine.

    Brian Pearlman (Moderator)

    Brian L. Pearlman, MD is Medical Director for Wellstar Atlanta Medical Center’s Center for Hepatitis C in Atlanta Georgia. He is also Professor of Medicine at the Medical College of Georgia and Professor of Medicine at Emory School of Medicine. Dr. Pearlman completed his medical degree at the University of Miami, Florida and his post-graduate training included both Diagnostic Radiology at University of Texas-Southwestern and Internal Medicine at Baylor University-Dallas, Texas.

    Dr. Pearlman is Faculty for the American College of Physicians (FACP), Fellow of the American Association for the Study of Liver Diseases (FAASLD), and members of the American Academy of HIV Medicine, and the American Gastroenterological Association. He sat on the Board of Directors for The American Liver Foundation’s Southeast Chapter. Dr. Pearlman is widely published in leading journals such as The Lancet, Gastroenterology, HEPATOLOGY, The American Journal of Gastroenterology, The Lancet Infectious Disease, Clinical Infectious Diseases and The American Journal of Medicine.

    Dr. Pearlman is active in both patient care and in teaching physicians. He has been the recipient of numerous teaching awards, and also an active investigator in multiple hepatitis C-related trials, some of which are in collaboration with the CDC’s Division of Viral Hepatitis.

  • 2020 Webinar: Prevention and Management of Ascites in Cirrhosis: Controversies and New Approaches

    Contains 2 Component(s) Recorded On: 03/10/2020

    Webinar hosted by the Portal Hypertension Special Interest Group on March 10, 2020.

    This webinar will review recent important advances in understanding of how to care for patients with cirrhosis and ascites. Specifically, it will discuss how to risk stratify patients for ascites and new strategies for ascites prevention. In addition, it will address evidence-based approaches to the management of ascites among patients who have chronic kidney disease, a challenging and common clinical scenario. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Scott W. Biggins (Moderator)

    Dr. Scott W. Biggins is Chief of Hepatology, Director of the Liver Care Line for UW Medicine, and Director of the Center for Liver Investigation Fostering Discovery (C-LIFE) at the University of Washington. Dr. Biggins is a national recognized clinician and researcher in the field of Hepatology. He received his undergraduate degree in chemical engineering (bioengineering option) from the University of California, Los Angeles (1994) and his medical degree from the University of Southern California (1999). He completed a residency in Internal Medicine at Oregon Health & Science University (2002) and his Gastroenterology fellowship training at the University of California, San Francisco (2005). He was also awarded a Master’s degree in Clinical Research from the University of California, San Francisco (2006).

    Dr. Biggins' clinical interests are the risk reduction and management of complications of end-stage liver disease, and the clinical evaluation and care of liver transplant candidates and recipients. He has been recognized as a fellow of American Association for the Study of Liver Diseases (FAASLD), American Society of Transplantation (FAST), and American Gastroenterological Association (AGAF). He is Vice Chair of the AASLD Special Interest Group (SIG) for Portal Hypertension.

    His research is focused on complications of portal hypertension, improving recipient and donor selection for liver transplantation and revising organ allocation algorithms in order to maximize patient outcomes. He has received research funding from the American Liver Foundation, National Institutes of Health and the Agency for Healthcare Research and Quality. He has published more than 75 papers in peer-reviewed journals including the New England Journal of MedicineGastroenterology, HEPATOLOGY, and Liver Transplantation.

    Elizabeth Verna (Moderator)

    Dr. Elizabeth Verna is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist.

    In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.

    Juan G. Abraldes

    Dr. Juan G. Abraldes is a Transplant Hepatologist, Professor and Director of the Liver Unit at the University of Alberta, Edmonton, Canada. He gained his MD in 1995 from the University of Santiago de Compostela, Spain, and got his Board Certificate in Gastroenterology and Hepatology at the Liver Unit, Hospital Clinic, University of Barcelona (2000). He did a postdoctoral training at Yale University (2003–2004). He was a faculty member of the Liver Unit, at Hospital Clinic Barcelona, until 2013, when he moved to the University of Alberta.

    He has published more than 200 papers on the pathophysiology, diagnosis and management of end-stage liver disease. He has co-authored the international Baveno guidelines for the management of portal hypertension in 2005, 2010 and 2015. He is the co-author of the American Association for the Liver Clinical Guidance for the management of varices and variceal bleeding in cirrhosis and was the chair of the AASLD Special Interest Group in Portal Hypertension between 2017 and 2018.

    Florence Wong

    Florence Wong, MD is a full professor at the University of Toronto and staff Hepatologist at the Toronto General Hospital, Ontario, Canada. She received her medical degree from the University of Melbourne, Australia and completed her postgraduate training in Australia and in Toronto, Canada. Apart from caring for a large population of patients with advanced liver cirrhosis, Dr. Wong has been active in research in the pathogenesis of portal hypertension, ascites formation, liver-kidney interaction, including the development of hepatorenal syndrome, and renal failure in cirrhosis for the past 28 years. She has received research funding from various funding agencies including the Canadian Institutes of Health Research, Canadian Liver Foundation and the National Institutes of Health.

    She has been the Secretary of the International Ascites Club, organizing two international meetings on the complications of ascites, she also held the position as the Chair of the Education Committee of the Canadian Association for the Study of the Liver. Recently, she served as the Chair of the "Acute-on-Chronic Liver Failure Special Interest Group" of the American Association for the Study of the Liver, and organizer of the Single Topic Symposium of Acute-on-Chronic Liver Failure. Currently, she is the Deputy Editor of Liver Transplantation. She is also the recipient of the Gold Medal from the Canadian Liver Foundation and the Canadian Association for the Study of the Liver for her contribution to academia in Hepatology.

    She has published widely on the topics related to ascites, and renal dysfunction in cirrhosis. She has more than 200 peer-reviewed publications as well as contributing regular reviews, book chapters and editorials on similar topics. She is currently on the writing committee to write the guidelines for the management of refractory ascites for the American Association for the Study of the Liver. Most recently, she has been responsible for putting together a landmark international document defining renal failure in cirrhosis.

  • 2020 Webinar: Implementation Science of Patient Reported Outcomes (PROs)

    Contains 2 Component(s) Recorded On: 02/27/2020

    Webinar hosted by the Public Health/Health care Delivery Special Interest Group on February 27, 2020.

    There is increasing interest to integrate patient reported outcomes (PROs) within routine practice to enhance and inform clinical care. It has shown to improve patient- provider communication, provider awareness of symptoms, tailored symptom management and enhanced quality of life. There is minimal knowledge on how to integrate PROMs within routine busy hepatology practice, and how to respond to the symptom scores assessed. We propose to conduct a webinar to discuss role of PROs in Hepatology, methods to integrate PROs within routine care, and learn how PROs are linked with healthcare quality. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Mayur Brahmania (Moderator)

    Dr. Mayur Brahmania is an Assistant Professor of Medicine at Western University practicing in Hepatology and Transplant Hepatology. After training in general and transplant Hepatology at the Toronto General Hospital: Toronto Centre for Liver Disease he undertook a research fellowship and earned a Masters of Public Health (MPH) degree at the Harvard TH Chan School of Public Health in Boston, MA. He also holds advanced certification from the Centre for Quality Improvement and Patient Safety (CQUIPS).

    Dr. Brahmania has been involved with the Choosing Wisely Canada (CWC) campaign as the Canadian Association for the Study of Liver Quality Lead. In this leadership role, he led the development of the 'top 5' list recommendations for Hepatology and his group is currently working to develop strategies to benchmark quality indicators for liver disease across Canada. 

    Dr. Brahmania is the current chair of the Gastroenterology Quality Improvement and Innovation Committee at Western University and currently focuses his research interests around quality improvement initiatives to advance and standardize quality of care in patients living with liver disease; many of these leading to publications in peer reviewed journals and presentation. 

    Rachel Sisodia

    Rachel Sisodia, MD is a gynecologic oncologist specializing in the care of women with cancer.  Her area of excellence is Clinical Expertise/Innovation in Surgery and Patient Reported Outcomes. Currently, she spends time serving as Medical Director for the Massachusetts General Physicians Organization (MGPO) and Medical Director for Partners Healthcare, where she is the Physician Executive responsible for the implementation, management and strategy of Patient Reported Outcomes (PROs) within the Partners Enterprise. In 2014, she joined the faculty at MGH and HMS, where she provides clinical care, supervise trainees and conduct research on operative/ peri-operative care with a goal of improving surgical outcomes for women with gynecologic malignancy. In addition to her work at MGH and HMS, she also travels to Southern New Hampshire Medical Center four days a month, where she works in a largely underserved area. 

    Dr. Sisodia has focused on developing best surgical practices in gynecologic oncology within her scope as a gynecologic oncologist. This work has resulted in peer reviewed publications on topics such as the role of hysterectomy in trophoblastic disease, the utility of the Surgical Apgar Score, debulking surgery for survival in ovarian cancer and risk factors for hospital readmission within 30 days of surgery.  She has presented this work on regional, national and international levels. This has taken the form of local and regional grand rounds, as well as multiple presentations of original research at the New England Association of Gynecologic Oncologists (NEAGO), where she won the 2012 award for Best Scientific Presentation. On a national scale her work has been presented at annual meetings for the Society of Gynecologic Oncology, Society for Gynecologic Investigation and the American Society for Clinical Oncology. She also spoken internationally on the evolving role of hysterectomy in the management of trophoblastic disease and have been instrumental in creating a monthly gynecologic oncology tumor board at Southern New Hampshire Medical Center where surgical and post-operative management is reviewed via an evidence-based approach, elevating the level of gynecologic cancer care in the community.    

    Manisha Verma

    Manisha Verma, MD, MPH, currently serves as the Director of Research at the Department of Digestive Diseases and Transplantation at Einstein Healthcare Network, Philadelphia, and as the Assistant Professor of Medicine, Research at Sidney Kimmel Medical College. Her program of research focuses on patient centered outcomes research (PCOR) within Hepatology and beyond.  She and her team received a 15 million research award from the Patient Centered Outcomes Research Institute to conduct a multi-site cluster randomized study to compare two models of palliative care delivery for ESLD. She has contributed to advances in knowledge of clinical applications of Health Services Research, specifically in the areas of clinical integration of patient reported outcomes assessments,  integrated care models (palliative care and behavioral health), and population-based health approaches. 

    In her role, she is responsible for promoting and facilitating leading edge research, including collaborative and interdisciplinary research, in areas related to the mission of the Department (to advance patient care, education and new treatments for liver diseases). She serves as the Steering Committee member for the American Association for Study of Liver Diseases (AASLD) Public Health / Healthcare Delivery Group and as the Vice Chair for the Education Subcommittee. Dr. Verma has won both the Albert Einstein Society Innovative Awards and Albert Einstein Society Research Awards as a Principal Investigator since 2015 onwards.  The studies supported from these awards have led to development of a PCOR Pillar within the Department. 

  • 2020 Webinar: NLRB - How Is It Working So Far?

    Contains 2 Component(s) Recorded On: 02/20/2020

    Webinar hosted by the Liver Transplantation journal on February 20, 2020.

    In the Spring of 2019, the National Liver Review Board was put into place. The purpose is to provide greater uniformity in assigning MELD exception scores. We have early data describing the initial outcomes of patients requesting MELD exception scores. There are also some early "lessons learned" in how to improve the process. Dissemination of this data would be helpful for practitioners requesting MELD scores for their patients. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    James F. Trotter

    Dr. Trotter is the Director of General and Transplant Hepatology at Baylor University Medical Center, part of Baylor Scott & White Health, and is fellowship-trained in hepatic transplantation and gastroenterology. His primary interests include end-stage liver disease, living donor liver transplantation, and the management of liver transplant candidates and recipients.

    Dr. Trotter works closely with local physicians to support the management and treatment of patients with liver disease and evaluate possible candidacy for transplantation at the liver outreach clinic in the Austin area. Dr. Trotter completed his medical training at University of Texas Southwestern Medical Center in Dallas before receiving fellowship training in gastroenterology and hepatic transplantation at Duke University Medical Center.

  • 2020 Webinar: Are You Digitally Secure?

    Product not yet rated Contains 2 Component(s) Recorded On: 02/18/2020

    Webinar hosted by the Communications and Technology Committee on February 18, 2020.

    Today’s high-profile hacks of major organizations and institutions have increased awareness of the issues of digital security, yet most people are compromising their privacy & security on a regular basis, which can put themselves – and their institution – at risk. Attendees at this webinar will better understand the digital risks and learn to separate truth from hype about how secure their presence is.

    Identify critical terms about digital security and privacy
    Understand how to best keep your personal digital presence from being compromised
    Learn over 5 tools that will greatly increase your online protection

    We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    James Spellos

    James Spellos is the President of Meeting U, a company specializing in helping people become more productive and comfortable with technology.

    Jim is certified as a Microsoft Office Specialist (MOS). He delivers more than 100 seminars annually on how to use technology more efficiently, and how it is altering the nature of business. He was a faculty member at New York University, teaching in the School of Professional and Continuing Studies for over 25 years. He was honored with both their Award for Teaching Excellence and their Outstanding Service Award.

    In 2014 Jim joined the Board of Directors for Rock and Wrap It Up, an anti-poverty, anti-hunger think tank, which supports food recovery for over 43,000 agencies in North America by recovering excess food from events. Jim co-created for them their Whole Earth Calculator app, which helps organizations identify the quantity of food donated and carbon footprint reduced by an organization helping to recover excess food from events.

    Jim is an accomplished musician and songwriter, and released his first solo recording, Stroke of Genius, at the end of 2019.

  • 2019 Webinar: Cannabis and the Liver: Update for the Hepatologist

    Contains 2 Component(s) Recorded On: 12/12/2019

    Webinar hosted by the Clinical Practice Special Interest Group on December 12, 2019.

    Use of cannabis is growing in the population with increased interest in potential medicinal use as well as recreational use depending on the jurisdiction. Given this, clinicians need to have an understanding about cannabis and its potential impacts on liver disease. This webinar will provide attendees information about cannabis, its major components (THC/CBD) as well as discuss potential policy implications regarding transplantation. As well, the literature regarding safety and potential benefits/harms will be reviewed in detail. We will utilize a live webinar format that will be recorded for on-demand viewing on LiverLearning®.

    Stephen Congly (Moderator)

    Dr. Stephen Congly is a Clinical Assistant Professor at the University of Calgary in the Division of Gastroenterology and Hepatology with a practice consisting of both general and transplant hepatology. He completed his internal medicine and gastroenterology training at the University of Calgary and subsequently a fellowship in Hepatology at the University of Calgary and in Transplant Hepatology at Mayo Clinic, Rochester, MN.

    He has a Master of Science in Health Economics, Policy and Management from the London School of Economics and is a member of the O'Brien Institute for Public Health at the University of Calgary. His research interests include health technology assessment, resource utilization, hepatocellular carcinoma and liver transplantation.

    Kevork Peltekian

    Dr. Peltekian is the head of Division of Digestive Care and Endoscopy at the Queen Elizabeth II Health Sciences Centre and Professor of Medicine and Surgery at Dalhousie University. Since 1995, he has been practicing as a specialist in liver disease and transplantation in Nova Scotia. Over the years, Dr. Peltekian has been frequently recognized for excellence in undergraduate and postgraduate education as well as research. He has over 80 peer-reviewed publications in high impact journals. Over the years, he has held major leadership roles with Chairman and Chief Executive Officer of the Canadian Liver Foundation 2005-2009 and President of the Canadian Association for Study of Liver 2012-2014.

    For his volunteer work and contributions to the fight against liver disease, Dr. Peltekian was awarded the Queen Elizabeth II Diamond Jubilee Medal. In 2017, Dr. Peltekian received the CASL Distinguished Service Award for his significant contributions to the practice of Hepatology in Canada. He has been a member of AASLD since 1993.

  • 2019 Clinical Hepatology Debrief

    Contains 2 Component(s) Recorded On: 11/12/2019

    Clinical Hepatology Debrief presented at The Liver Meeting® 2019.

    Review a condensed summary of the clinical research highlights from The Liver Meeting.

    Michael R. Charlton

  • 2019 Leon Schiff State-of-the-Art Lecture: Molecular Pathogenesis and Management of Hepatocellular Carcinoma

    Contains 2 Component(s) Recorded On: 11/12/2019

    Leon Schiff State-of-the-Art Lecture: Molecular Pathogenesis and Management of Hepatocellular Carcinoma presented at The Liver Meeting® 2019.

    At the 2019 Leon Schiff State-of-the-Art Lecture, our selected speaker will provide a thorough overview of the advances in knowledge of the pathogenesis of hepatocellular carcinoma (HCC). The lecture will explore current data on evidence-based treatment of this disease, including novel molecular therapies and advances in precision oncology.

    David Kaplan
    Josep Llovet